A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C
Latest Information Update: 08 May 2025
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Sacituzumab Tirumotecan (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 15 Jul 2024 New trial record
- 10 Jul 2024 Status changed from not yet recruiting to recruiting.